News

Updates from BCI

BCIlanyard

Navigate via the main menu, post Categories to the right or Tags below. Join the discussion!

Prof Trevor Graham part of ‘ACE’ research centre within NCI’s Cancer Systems Biology Consortium

Posted in General News, Grants & Awards Published by Bethan Warman 19 June 2018

Prof Trevor Graham part of ‘ACE’ research centre within NCI’s Cancer Systems Biology Consortium

BCI’s Prof Trevor Graham, Lead of the Evolution and Cancer Biology Laboratory, is part of Arizona State University’s recently funded research centre called ‘ACE’ (the Arizona Cancer Evolution Centre), which has been awarded more than $8.5 million over five years to serve as one of 13 research hubs within the National Cancer Institute (NCI)’s Cancer Systems Biology Consortium (CSBC).

NCI’s CSBC has a multidisciplinary approach, with the network of centres uniting clinical and basic cancer researchers with physical scientists, engineers, mathematicians and computer scientists to tackle key questions in cancer biology in novel ways.

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Posted in General News, Conferences, BCI on the Road Published by Bethan Warman 15 June 2018

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. The Centre Lead of our Centre for Experimental Cancer Medicine (CECM), Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles of the CECM and Director of the Barts Cancer Centre, presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.

Research explainer: Mis-segregation of human chromosomes

Posted in General News, Publications Published by Bethan Warman 13 June 2018

Research explainer: Mis-segregation of human chromosomes

Dr Sarah McClelland from Barts Cancer Institute, Queen Mary University of London, has recently published new research in the journal Cell Reports revealing new insights into why cell division can sometimes go wrong.

In this Q & A, she explains why chromosomes can end up in the wrong places when dividing and highlights two particular chromosomes that seem to be more prone to the issue than others.

Research suggests improved detection rates are needed to maximise cancer prevention

Posted in General News, Publications Published by Bethan Warman 08 June 2018

Research suggests improved detection rates are needed to maximise cancer prevention

Current detection strategies are found to have identified only 2.6% of the BRCA gene mutation carriers in the Greater London population, according to a recent study published in the Journal of Medical genetics. The findings of the study, performed by researchers from the BCI’s Centre for Experimental Cancer Medicine, led by Dr Ranjit Manchanda, suggest that enhanced and new approaches are required to maximise the opportunity for breast and ovarian cancer prevention.

BRCA1 and BRCA2 mutations are associated with an increased risk of breast and ovarian cancer. A recent study has shown that about 72 and 69% of women who inherit a harmful mutation in the BRCA1 and BRCA2 genes, respectively, develop breast cancer by 80 years of age. Additionally, 44 and 17% of women who inherit a harmful mutation in the BRCA1 and BRCA2 genes, respectively, develop ovarian cancer by 80 years of age. Identifying mutation carriers is therefore critical to reduce the number of BRCA-associated cancers.

Forecasting the evolution of cancer

Posted in General News, Publications Published by Bethan Warman 28 May 2018

Predicting the trajectory of tumour growth

Forecasting the evolution of cancer

New research, published today in Nature Genetics, has developed a computer model that forecasts the changes that occur within tumours as they develop. In the future, it is hoped that such a model may enable the prediction of the trajectory of tumour growth in patients, allowing clinicians to pre-empt disease course and tailor treatment regimens accordingly.

The model was developed in collaboration with researchers from BCI’s Centre for Tumour Biology, led by Prof Trevor Graham (Lead for the Evolutionary and Cancer Biology Laboratory), the Institute of Cancer Research, led by Dr Andrea Sottoriva, and University College London, led by Dr Chris Barnes.

International Clinical Trials Day 2018

Posted in General News Published by Bethan Warman 21 May 2018

International Clinical Trials Day 2018

International Clinical Trials Day is celebrated on 20th May each year in recognition of the clinical trials conducted around the world, which ensure that research from the laboratory can be translated into patient benefit. The progress that is continuing to be made in cancer research, resulting in cancer survival rates doubling in the last 40 years, would not be possible without the researchers, clinicians, nurses and, of course, patients that are involved in clinical trials each year.

Fellows inaugurated at new Rutherford Academy of Population Genomics and Health Data Science

Posted in General News, Grants & Awards Published by Bethan Warman 16 May 2018

Fellows inaugurated at new Rutherford Academy of Population Genomics and Health Data Science

Queen Mary University of London has appointed four research fellows to its new Rutherford Academy of Population Genomics and Health Data Science, funded by the Medical Research Council and UK Research and Innovation’s Rutherford Fund. Two of the fellows include BCI’s Dr Kit Curtius and Dr Dayem Ullah.

Queen Mary’s new Rutherford Academy will be aligned to its research as a partner of the London substantive site of Health Data Research UK - a major new initiative to transform health through data science. Forty two of these prestigious fellowships were awarded following a rigorous national competition, resulting in four fellowships at Queen Mary out of a total of fourteen awarded to London universities.

London Pancreas Workshop 2018

Posted in General News, BCI Spotlight Articles, Events Published by Bethan Warman 11 May 2018

A forum for state-of-the-art clinical and basic research in pancreatic cancer

London Pancreas Workshop 2018

On Friday 4th May, BCI hosted the seventh London Pancreas Workshop, co-organised by Prof Hemant Kocher and our Director Prof Nick Lemoine, which attracted delegates from across Europe and America, with over 140 attendees in total. The biennial event is recognised as a forum for state-of-the-art clinical and basic research in pancreatic cancer.

The areas of focus for this year’s workshop were diagnostics, clinical trials and preclinical work for targeting pancreatic cancer. We heard a variety of interesting talks in these areas, delivered by researchers renowned in their fields.

Research reveals how breast cancer drug can accelerate cancer cell growth

Posted in General News, Publications Published by Bethan Warman 01 May 2018

Research reveals how breast cancer drug can accelerate cancer cell growth

The breast cancer drug lapatinib which is designed to shrink tumours can sometimes cause them to grow in the lab, according to a new study published in eLife. By understanding the molecular basis of this phenomenon, scientists hope that their findings will lead to safer treatment options and drug design in the future.

Lapatinib is used in combination with other cancer drugs and chemotherapy to treat patients with a particular type of advanced breast cancer, but failed clinical trials as a stand-alone treatment.

Using a modified adenovirus to overcome treatment resistance in prostate cancer

Posted in General News, Publications Published by Bethan Warman 27 April 2018

Using a modified adenovirus to overcome treatment resistance in prostate cancer

Researchers from BCI’s Centre for Molecular Oncology, led by Dr Gunnel Halldén, have identified a mechanism by which a modified flu-like virus, called AdDD, is able to negate resistance to a drug called mitoxantrone and increase tumour cell killing in prostate cancer models. This mechanism is dependent on B-cell lymphoma 2 (Bcl-2)- a protein involved in the regulation of cell death (apoptosis).

Recent statistics have shown that prostate cancer is now the third biggest cancer killer in the UK, claiming the life of one man every 45 minutes. Here at the BCI, prostate cancer is a key focus of research and our researchers endeavour to identify factors that influence prostate cancer progression and therapeutic response.

<<  1 2 [34 5 6  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.